Onkologie. 2022:16(4):212-214 | DOI: 10.36290/xon.2022.040

Treatment of a senior patient with cardiovascular comorbidities using checkpoint inhibitor therapy

Kristián Hrušák1, Tomáš Büchler1, Jana Votrubová2
1 Onkologická klinika, 1. LF UK a Thomayerova nemocnice, Praha
2 Radiodiagnostické oddělení, Thomayerova nemocnice, Praha

This case study describes a long-term survival of a senior patient with metastatic kidney cancer and a number of cardiovascular comorbidities after a treatment by checkpoint inhibitors.

Keywords: kidney cancer, checkpoint inhibitors, geriatric oncology, comorbidities.

Accepted: August 22, 2022; Published: August 24, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrušák K, Büchler T, Votrubová J. Treatment of a senior patient with cardiovascular comorbidities using checkpoint inhibitor therapy. Onkologie. 2022;16(4):212-214. doi: 10.36290/xon.2022.040.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bai X, Yi M, Dong B, et al. The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017. Exp Hematol Oncol. 2020;9:27. [Cited 2020 Sep 29]. doi: 10.1186/s40164-020-00181-3. Go to original source... Go to PubMed...
    2. Rapoport BL, Westman H. Fast Facts: Managing immune-related Adverse Events in Oncology, Early recognition, prompt intervention, effective management. Karger Publishers, 2019. Go to original source...
    3. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Go to original source... Go to PubMed...
    4. Kalra S, Atkinson BJ, Matrana MR, et al. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016;117(5):761-765. doi: 10.1111/bju.13185. Go to original source... Go to PubMed...
    5. Huang XZ, Gao P, Song YX, et al. Efficacy of immune checkpoint inhibitors and age in cancer patients. Immunotherapy. 2020;12(8):587-603. doi: 10.2217/imt-2019-0124. Go to original source... Go to PubMed...
    6. Paderi A, Fancelli S, Caliman E, et al. Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study. Curr Oncol. 2021;28(5):3259-3267. [Cited 2021 Aug 25]. doi: 10.3390/curroncol28050283 Go to original source... Go to PubMed...
    7. Gomes F, Lorigan P, Woolley S, et al. A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study. ESMO Open. 2021;6(1):100042. doi: 10.1016/j.esmoop.2020.100042. Go to original source... Go to PubMed...
    8. Kanesvaran R, Le Saux O, Motzer R, et al. Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. Lancet Oncol. 2018;19(6):e317-e326. doi: 10.1016/S1470-2045(18)30125-6. Go to original source... Go to PubMed...
    9. Zeng X, Zhu S, Xu C, et al. Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy. Med Sci Monit. 2020;26:e922576. [Cited 2020 Sep 7]. doi: 10.12659/MSM.922576. Go to original source... Go to PubMed...
    10. Nemoto Y, Ishihara H, Nakamura K, et al. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. Int Urol Nephrol. 2022;54(1):47-54. doi: 10.1007/s11255-021-03042-y. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.